

Guray Saydam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1747139/publications.pdf>

Version: 2024-02-01

139
papers

1,548
citations

331538

21
h-index

360920

35
g-index

140
all docs

140
docs citations

140
times ranked

2236
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells. <i>Medical Oncology</i> , 2022, 39, 46.	1.2	5
2	Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis. <i>Medical Oncology</i> , 2022, 39, 29.	1.2	1
3	Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. <i>Expert Review of Hematology</i> , 2022, 15, 97-106.	1.0	4
4	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. <i>Lancet Haematology</i> , 2022, 9, e480-e492.	2.2	18
5	<i>Origanum Sipyleum</i> Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells. <i>Nutrition and Cancer</i> , 2022, 74, 3679-3691.	0.9	0
6	Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1033-1042.	0.4	0
7	The Effect of Cryotherapy on the Prevention of Oral Mucositis and on the Oral pH Value in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151146.	0.7	5
8	Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or Without Aplastic Anemia: Multicenter Turkish Experience. <i>Turkish Journal of Haematology</i> , 2021, 38, 195-203.	0.2	0
9	Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. <i>Hematological Oncology</i> , 2021, 39, 498-505.	0.8	12
10	Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data. <i>Turkish Journal of Haematology</i> , 2021, 38, 273-285.	0.2	2
11	PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. <i>European Journal of Pharmacology</i> , 2021, 910, 174446.	1.7	8
12	Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis. <i>American Journal of Blood Research</i> , 2021, 11, 279-285.	0.6	0
13	An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy. <i>Blood</i> , 2021, 138, 4730-4730.	0.6	0
14	The effect of malnutrition on mortality in hospitalized patients with hematologic malignancy. <i>Supportive Care in Cancer</i> , 2020, 28, 1441-1448.	1.0	77
15	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2565-2576.	0.8	19
16	A histopathological scoring and grading system to predict outcome for patients with AA amyloidosis. <i>International Urology and Nephrology</i> , 2020, 52, 1297-1304.	0.6	5
17	TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. <i>British Journal of Haematology</i> , 2020, 190, 869-876.	1.2	40
18	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. <i>Blood</i> , 2020, 136, 40-41.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 2316-2323.	0.9	14
20	Investigating the cytotoxic and apoptotic effects of sunitinib upon K-562 chronic myelogenous leukemia cell line and assessment of gene profiling. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 150.	0.3	1
21	Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythaemia Vera: a Multicentre Chart Review Study. <i>Turkish Journal of Haematology</i> , 2020, 37, 177-185.	0.2	1
22	Retrospective Analysis of Hairy Cell Leukemia Patients Treated with Different Modalities as First Line: Real-Life Experience Over 20 Years. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 692-698.	0.3	1
23	Effects of Rituximab on JAK-STAT and NF- κ B signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia. <i>Turkish Journal of Biochemistry</i> , 2019, 44, 499-509.	0.3	2
24	The effect of polycythemia vera on hearing functions: Evaluation of twenty-one patients. <i>Clinical Otolaryngology</i> , 2019, 44, 434-437.	0.6	4
25	Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 4555-4563.	1.2	1
26	A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia. <i>Turkish Journal of Haematology</i> , 2019, 36, 230-237.	0.2	8
27	Role of Allogeneic Stem Cell Transplant in the Treatment of Primary Myelofibrosis. <i>Experimental and Clinical Transplantation</i> , 2019, 17, 93-96.	0.2	1
28	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. <i>Annals of Hematology</i> , 2018, 97, 617-627.	0.8	23
29	Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line. <i>Gene</i> , 2018, 647, 213-220.	1.0	17
30	Efficacy and Safety of Ruxolitinib in 132 Turkish Patients with Myelofibrosis: A Multicenter and Retrospective Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S265.	0.2	1
31	Adult Onset Langerhans Cell Histiocytosis: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S269.	0.2	0
32	Castleman's Disease: The Experience Over 17 Years. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S270.	0.2	0
33	Successful Treatment of Patients with AML and MDS by Decitabine: Single Centre Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S260-S261.	0.2	0
34	Clinical Features and Outcomes of Solitary Plasmacytomas: Single-Center Experience from Turkey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S235.	0.2	0
35	Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 80-83.	0.4	6
36	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. <i>Annals of Hematology</i> , 2018, 97, 1591-1600.	0.8	53

#	ARTICLE	IF	CITATIONS
37	Frontline nilotinib treatment in Turkish patients with Philadelphia chromosomeâ€“positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. <i>Hematology</i> , 2018, 23, 771-777.	0.7	5
38	Polycythemia vera: diagnosis, clinical course, and current management. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 698-710.	0.4	12
39	Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 777-785.	0.4	3
40	Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study. <i>Blood</i> , 2018, 132, 1754-1754.	0.6	3
41	Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1397-1402.	0.3	0
42	Report On Three Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Turkish Journal of Haematology</i> , 2018, 35, 211-212.	0.2	1
43	Acquired haemophilia A in an elderly patient related to relapsed cervix carcinoma. <i>The Journal of Haemophilia Practice</i> , 2018, 5, 143-146.	0.2	0
44	Response: upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 327-328.	0.9	0
45	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. <i>Lancet Oncology</i> , The, 2017, 18, 88-99.	5.1	205
46	Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia. <i>Gene</i> , 2017, 637, 173-180.	1.0	11
47	Risk factors for poor mobilization in solid tumors: How effectively can we mobilize patients with solid tumors?. <i>Transfusion and Apheresis Science</i> , 2017, 56, 809-813.	0.5	1
48	Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.3	2
49	Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells. <i>Turkish Journal of Biology</i> , 2017, 41, 926-934.	2.1	2
50	Epidemiology and analysis of invasive fungal infections in patients with hematological malignancies: a single-center real-life experience. <i>Turkish Journal of Medical Sciences</i> , 2017, 47, 1535-1542.	0.4	3
51	Retrospective analysis of primary gastric diffuse large B-cell lymphoma: a single center study from Turkey. <i>Turkish Journal of Medical Sciences</i> , 2017, 47, 240-245.	0.4	3
52	Retrospective analysis of patients with relapsed or refractory testicular nonseminous germ cell tumors treated with autologous stem cell transplantation. <i>Indian Journal of Cancer</i> , 2017, 54, 415.	0.2	3
53	Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. <i>Turkish Journal of Haematology</i> , 2017, 34, 27-33.	0.2	10
54	The role of PET/CT in evaluation of bone marrow involvement in lymphoma patients at the initial staging. <i>Marmara Medical Journal</i> , 2017, 30, 1-1.	0.2	4

#	ARTICLE	IF	CITATIONS
55	TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2017, 34, 174-178.	0.2	2
56	Progressive Transformation of Germinal Centers: Single-Center Experience of 33 Turkish Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S149-S151.	0.2	4
57	The Effect of Polycythemia Vera on Hearing Functions. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S94-S95.	0.2	0
58	Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosomeâ€“positive chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2016, 17, 1851-1858.	0.9	6
59	Toxic epidermal necrolysis associated with radiotherapy and phenytoin in a patient with non-Hodgkin's lymphoma: A case report. Reports of Practical Oncology and Radiotherapy, 2016, 21, 81-83.	0.3	2
60	Ruxolitinib induces autophagy in chronic myeloid leukemia cells. Tumor Biology, 2016, 37, 1573-1579.	0.8	13
61	Molecular Subtype Distribution and Cyclooxygenase-2 Expression Situation in Inflammatory Breast Cancer. Meandros Medical and Dental Journal, 2016, 17, 54-58.	0.1	0
62	miR17 Suppresses Cell Proliferation in Zoledronic Acid Treated Chronic Myeloid Leukemia Cells by Inducing Autophagy. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S213.	0.2	0
63	Evaluation of Febrile Neutropenic Episodes in Autologous Hematopoietic Stem Cell Transplantations for Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S40-S41.	0.2	0
64	18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement. Clinical Nuclear Medicine, 2015, 40, 873-876.	0.7	12
65	Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turkish Journal of Haematology, 2015, 32, 323-328.	0.2	7
66	Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria. Case Reports in Hematology, 2015, 2015, 1-5.	0.3	7
67	Peripheral blood stem cell mobilization from healthy donors. Transfusion and Apheresis Science, 2015, 53, 13-16.	0.5	20
68	Ocular Adnexal Lymphomas: Single-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S158-S160.	0.2	5
69	Investigating the Role of JAK/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S161-S166.	0.2	17
70	Investigating The Role of JAK/STAT Pathway upon Dasatinib Induced Apoptosis for CML Cell Model K562. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S209-S210.	0.2	0
71	Resveratrol Increases CHD4 Gene Expression and Regulates Wnt Signaling in Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S215.	0.2	0
72	Ocular Adnexal Lymphomas: Experience of Single Center. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S217.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Evaluation of Febrile Neutropenic Episodes in Autologous Hematopoietic Stem Cell Transplantations for NHL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S71-S72.	0.2	0
74	Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?. <i>Saudi Pharmaceutical Journal</i> , 2015, 23, 14-21.	1.2	5
75	Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease. <i>Current Medicinal Chemistry</i> , 2015, 22, 1956-1962.	1.2	7
76	Seasonal Association of Immune Thrombocytopenia in Adults. <i>Balkan Medical Journal</i> , 2015, 32, 347-351.	0.3	7
77	Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. <i>American Journal of Blood Research</i> , 2015, 5, 1-9.	0.6	22
78	PNH is a debilitating, fatal but treatable disease: same disease, different clinical presentations. <i>American Journal of Blood Research</i> , 2015, 5, 30-3.	0.6	3
79	Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells. <i>Tumor Biology</i> , 2014, 35, 7861-7870.	0.8	8
80	RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7128-TPS7128.	0.8	3
81	The Clinical Characteristics and Therapeutic Outcomes of Elderly Patients with Chronic Lymphocytic Leukemia: A Retrospective Multicenter Study. <i>Blood</i> , 2014, 124, 5644-5644.	0.6	1
82	Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update. <i>Blood</i> , 2014, 124, 5532-5532.	0.6	0
83	Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K562 with unmodified or chemically modified siRNAs and induction of apoptosis. <i>Annals of Hematology</i> , 2013, 92, 151-162.	0.8	23
84	STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 527-532.	2.5	11
85	Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly: Experience of a single center from Turkey. <i>Pathology Research and Practice</i> , 2013, 209, 471-478.	1.0	10
86	Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment. <i>Molecular Biology Reports</i> , 2013, 40, 1591-1597.	1.0	3
87	Quality of Life and Supportive Care in Multiple Myeloma. <i>Turkish Journal of Haematology</i> , 2013, 30, 234-246.	0.2	31
88	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. <i>Turkish Journal of Haematology</i> , 2013, 30, 351-358.	0.2	14
89	Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2742-2742.	0.6	0
90	Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis. <i>American Journal of Blood Research</i> , 2013, 3, 58-70.	0.6	14

#	ARTICLE	IF	CITATIONS
91	Granulocytic sarcoma: a systematic review. American Journal of Blood Research, 2013, 3, 265-70.	0.6	95
92	Metastatic Pulmonary Calcinosis and Leukocytoclastic Vasculitis in a Patient with Multiple Myeloma. Turkish Journal of Haematology, 2012, 29, 397-400.	0.2	4
93	Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. Journal of Blood Medicine, 2012, 3, 139.	0.7	14
94	Non-Hodgkinâ€™s Lymphoma of the Breast: Report of Five Cases and Review of the Literature. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2012, 22, 195-201.	0.1	0
95	MOLECULAR EVALUATION OF t(14;18)(bcl-2/IgH) TRANSLOCATION IN FOLLICULAR LYMPHOMA AT DIAGNOSIS USING PARAFFIN-EMBEDDED TISSUE SECTIONS. Turkish Journal of Haematology, 2012, 29, 126-134.	0.2	1
96	Methylprednisolone induces apoptosis by interacting with the JAK/STAT pathway in HL-60 and K-562 leukemic cells. Hematology, 2012, 17, 93-99.	0.7	8
97	The Potential Role of STAT's in Anti-Leukemic Therapy with Different Drugs. Blood, 2012, 120, 5120-5120.	0.6	0
98	Autophagic and Apoptotic Effects of Tyrosine Kinase Inhibitors in Myeloid Leukemia: Comparison of Three Generation. Blood, 2012, 120, 4915-4915.	0.6	0
99	Polyethylene Glycol - Polyethylenimine Nanoparticle-Mediated Transfection of Mir-150 Into the Leukemia Cells and Determination of the Expression Pattern Changes in Apoptosis and Cell Cycle Genes. Blood, 2012, 120, 4679-4679.	0.6	0
100	Resveratrol Triggers Apoptosis Through Regulating Ceramide Metabolizing Genes in Human K562 Chronic Myeloid Leukemia Cells. Nutrition and Cancer, 2011, 63, 637-644.	0.9	42
101	Caffeic acid phenethyl ester triggers apoptosis through induction of loss of mitochondrial membrane potential in CCRF-CEM cells. Journal of Cancer Research and Clinical Oncology, 2011, 137, 41-47.	1.2	21
102	The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60 acute myeloid leukemia cells. Journal of Cancer Research and Clinical Oncology, 2011, 137, 279-286.	1.2	46
103	Quercetin-induced apoptosis involves increased hTERT enzyme activity of leukemic cells. Hematology, 2011, 16, 303-307.	0.7	30
104	Factor V G1691A (Leiden) and prothrombin G20210A gene mutation status, and thrombosis in patients with chronic myeloproliferative disorders. Turkish Journal of Haematology, 2011, 2011, 306-311.	0.2	2
105	A case of acute lymphoblastic leukemia with additional chromosomes X and 5 associated with a Philadelphia chromosome in the bone marrow. Turkish Journal of Haematology, 2010, 27, 299-302.	0.2	1
106	Gossypol exerts its cytotoxic effect on HL-60 leukemic cell line via decreasing activity of protein phosphatase 2A and interacting with human telomerase reverse transcriptase activity. Hematology, 2010, 15, 144-150.	0.7	5
107	Experimental Repair of Rabbit Segmental Bone Defects by Using Autologous Bone Marrow and Electrical Stimulation. Turkiye Klinikleri Journal of Medical Sciences, 2010, 30, 623-630.	0.1	0
108	Effects of Hormone Replacement Therapy on Insulin Resistance and Platelet Function Tests. Medical Principles and Practice, 2009, 18, 43-47.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2009, 19, 195-204.	0.1	5
110	Radioisotope synovectomy with rhenium186in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia, 2008, 14, 518-523.	1.0	40
111	Primary cutaneous Bâ€cell lymphoma: report of eight cases and review of the literature. International Journal of Dermatology, 2008, 47, 675-680.	0.5	3
112	The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. Hematology, 2008, 13, 215-223.	0.7	3
113	Protein phosphatase 2A (PP2A) has a potential role in CAPE-induced apoptosis of CCRF-CEM cells via effecting human telomerase reverse transcriptase activity. Hematology, 2007, 12, 519-525.	0.7	9
114	Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: A case report. Hematology, 2007, 12, 489-492.	0.7	7
115	Clinical side effects during peripheral blood progenitor cell infusion. Transfusion and Apheresis Science, 2007, 36, 95-101.	0.5	54
116	Overnight refrigerator storage of autologous peripheral progenitor stem cells without cryopreservation. Transfusion and Apheresis Science, 2007, 36, 313-319.	0.5	9
117	Enteral resveratrol supplementation attenuates intestinal epithelial inducible nitric oxide synthase activity and mucosal damage in experimental necrotizing enterocolitis. Journal of Pediatric Surgery, 2007, 42, 1687-1694.	0.8	33
118	Amyloid deposition in knee and ankle joints in the course of multiple myeloma. Joint Bone Spine, 2007, 74, 209-211.	0.8	4
119	Potential involvement of serine/threonine protein phosphatases in apoptosis of HepG2 cells during selenite treatment. Biological Trace Element Research, 2007, 117, 65-75.	1.9	3
120	Red grape seed extract and its compound resveratrol exert cytotoxic effect to various human cancer lines. Turkish Journal of Haematology, 2007, 24, 102-9.	0.2	2
121	Dural plasmacytoma mimicking meningioma in a patient with multiple myeloma. Journal of Clinical Neuroscience, 2006, 13, 259-261.	0.8	37
122	Possible hepatosplenic candidiasis treated with liposomal amphotericin B and caspofungin combination. Journal of Infection, 2006, 52, 387-388.	1.7	4
123	Radioisotope Synovectomy for Treating Chronic Synovitis in Inhibitor Patients with Hemophilia.. Blood, 2006, 108, 4005-4005.	0.6	1
124	Induction of apoptosis by fatty acid ethyl esters in HepG2 cells. Food and Chemical Toxicology, 2005, 43, 139-145.	1.8	21
125	Biochemical and Morphological Characteristics of Selenite-Induced Apoptosis in Human Hepatoma Hep G2 Cells. Biological Trace Element Research, 2004, 99, 027-040.	1.9	12
126	Cytotoxic and inhibitory effects of 4,4â€²-dihydroxy chalcone (RVC-588) on proliferation of human leukemic HL-60 cells. Leukemia Research, 2003, 27, 57-64.	0.4	48

#	ARTICLE	IF	CITATIONS
127	Involvement of protein phosphatase 2A in interferon- γ -2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. <i>Leukemia Research</i> , 2003, 27, 709-717.	0.4	46
128	Potential Involvement of Calcineurin in Regulating the State of Differentiation and Apoptosis of HL-60 Cells During Methylprednisolone-Treatment. <i>Turkish Journal of Haematology</i> , 2003, 20, 143-51.	0.2	1
129	Acral Sclerosis due to Interferon-Alpha-2b in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2002, 107, 43-45.	0.7	2
130	Which dosing scheme is suitable for the taxanes? anin vitro model. <i>Archives of Pharmacal Research</i> , 2002, 25, 550-555.	2.7	6
131	Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. <i>Leukemia Research</i> , 2002, 26, 391-398.	0.4	24
132	Elevation of serum eosinophil cationic protein, soluble tumor necrosis factor receptors and soluble intercellular adhesion molecule-1 levels in acute bronchial asthma. <i>Journal of Investigational Allergy and Clinical Immunology</i> , 2002, 12, 211-4.	0.6	5
133	Vena cava superior syndrome due to sternal plasmacytoma in the course of systemic myeloma. <i>Haematologia</i> , 2002, 32, 529-33.	0.2	2
134	Intracranial Venous Thrombosis Associated with Severe Antithrombinâ€”III Deficiency in Pregnancy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2001, 27, 81-84.	0.6	4
135	Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. <i>Leukemia Research</i> , 1999, 23, 507-512.	0.4	22
136	Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. <i>Oncology Reports</i> , 0, , .	1.2	1
137	Hemophilia Patientsâ€™ Level of Knowledge of About Viral Hepatitis. <i>Mediterranean Journal of Infection, Microbes and Antimicrobials</i> , 0, , .	0.2	0
138	Is Allogeneic Stem Cell Transplantation a Good Option for Paroxysmal Nocturnal Haemoglobinuria?. <i>European Medical Journal Hematology</i> , 0, , .	0.0	0
139	Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 0, , .	0.7	0